Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma.
Bioanalysis
COVID-19
Favipiravir
Pharmacokinetics
SARS-CoV-2
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
24
03
2023
revised:
21
04
2023
accepted:
30
04
2023
medline:
12
6
2023
pubmed:
7
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
Favipiravir (FVP) is a broad-spectrum antiviral that selectively inhibits viral RNA-dependent RNA polymerase, first trialled for the treatment of influenza infection. It has been shown to be effective against a number of RNA virus families including arenaviruses, flaviviruses and enteroviruses. Most recently, FVP has been investigated as a potential therapeutic for severe acute respiratory syndrome coronavirus 2 infection. A liquid chromatography tandem mass spectrometry method for the quantification of FVP in human plasma has been developed and validated for use in clinical trials investigating favipiravir as treatment for coronavirus disease-2019. Samples were extracted by protein precipitation using acetonitrile, using
Identifiants
pubmed: 37148698
pii: S0731-7085(23)00205-4
doi: 10.1016/j.jpba.2023.115436
pii:
doi:
Substances chimiques
formic acid
0YIW783RG1
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115436Subventions
Organisme : Medical Research Council
ID : MR/V028391/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.